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Introduction Relevant Medications and Laboratory Values Discussion and Treatments
Acquired Hemophilia A (AHA) is a rare autoimmune condition characterized by
spontaneous synthesis of IgG against Factor VIII (FVIII) occurring with an incidence of
approximately 1.5 per million per year, with an approximate 9-22% rate of mortality. Unlike
congenital hemophilia, AHA occurs in males and females with incidence increasing with
age. Disease phenotype may range from asymptomatic, presenting with abnormal lab values,
to severe, with significant life-threatening or fatal bleeding. Patients often present with
widespread subcutaneous bleeds, muscle hematomas, urogenital tract bleeding and mucosal
bleeding. Unlike Congenital Hemophilia A, hemarthroses are uncommon. Patients remain at
risk of life-threatening bleeding until the inhibitor has been eradicated. The factor VIII level
and the inhibitor titer are not predictive of bleeding occurrences or the severity of bleeding
events. The diagnosis of AHA is confirmed by the presence of an isolated prolongation of
aPTT, non correcting mixing study, reduced FVIII levels and evidence of FVIII inhibitor.
The following patient provides an example of a case of Acquired Hemophilia A.
The goal of treatment in AHA is to reduce the duration of time at which the patient is at risk
of life threatening bleeding events, this is achieved through inhibitor eradication. Although
spontaneous remission may occur, the standard is to initiate treatment as soon as AHA has
been identified. Treatment regimens largely consist of glucocorticoids alone,
glucocorticoids and cyclophosphamide, and glucocorticoids and rituximab. Glucocorticoids
alone may achieve eradication in approximately 30% of cases. The addition of
cyclophosphamide may improve response to therapy to 60-100%. Although use of
cyclophosphamide has been shown to improve inhibitor eradication a substantial
proportion of patients die as a result of neutropenia-related infections. Combination therapy
of prednisone and cyclophosphamide is largely regarded as the most effective standard
first-line immune suppressive therapy to achieve inhibitor eradication. Despite this, up to
one third of patients may not respond to initial treatment of steroids and cyclophosphamide.
Rituximab has been implicated as an effective treatment option for patients resistant to
initial therapy. The efficacy of IVIG remains unclear. A prospective study of 19 patients
treated with IVIG demonstrated a ≥ 25% decline of inhibitor titer in 8 of 16 assessable
patients. Of note, patients achieving complete remission were noted to have low baseline
inhibitor levels, one of which additionally received glucocorticoids.
Our patient presented with high titers of FVIII inhibitor. Initiation of prednisone therapy,
with the addition of cyclophosphamide on day 3 of treatment, resulted in paradoxical
increase inhibitor titers. A fall in titer levels correlates with the addition of weekly
rituximab to the treatment regimen. Of note, cyclophosphamide was discontinued prior to
inhibitor eradication. Final eradication of the inhibitor was achieved with continued
prednisone and rituximab. Our patient also received 2 doses of IVIG between the second
and third doses of rituximab. Examining the inhibitor titers during the treatment course
suggests that rituximab was an important element of our treatment regimen. However, it is
difficult to come to a conclusion on the true efficacy of components in our treatment
regimen.
An important consideration of immunosuppressive therapy is risk of infection., particularly
in an elderly patient. A two year observational study by Collins et al., included 172 patients
with a median age of 78 years. Sepsis resulting from immunosuppression was the most
commonly reported adverse event and contributed to the death in 12 patients. Following
eradication our patient experienced multiple hospital readmission
Case Description
Conclusion
The patient is 78 year-old-male with a recent hospitalization for ESBL UTI and small bowel
obstruction that was complicated by a right femoral DVT. He returned to the hospital with
chief complaint of weakness, fatigue, exertional dyspnea and diffuse ecchymosis while on
Xarelto. Admission labs revealed a Hgb of 8.0 with a significantly elevated PTT of 199
without prior personal or family history of coagulopathy. Subsequent evaluation
demonstrated non corrective mixing studies, preliminary FVIII activity of 0.26% (normal
50-150%) and FVIII inhibitor level of 112.0 Bestheda units (BU). The patient’s hospital
course was complicated by development of significant right lower extremity hematoma and
recurrent drops in hemoglobin. During admission the patient required multiple transfusions
of blood products, including multiple transfusions of FEIBA (factor eight inhibitor bypassing
activity) for continued spontaneous bleeding.
The patient was initially treated with prednisone 1mg/kg and Cyclophosphamide 2mg/kg
daily. There was minimal change of FVIII activity/inhibitor levels after seven days. The
cyclophosphamide dose was subsequently increased to 3mg/kg daily and 800mg Rituximab
weekly for four weeks and adjuvant IVIG 1g/kg for two days were added.
Cyclophosphamide was discontinued after 19 days of therapy due to neutropenia. While the
FVIII inhibitor levels decreased promptly after giving Rituximab, FVIII activity remained
relatively stagnant throughout the treatment course until the inhibitor level breached 10 BU.
Over the 35 day admission, The FVIII inhibitor decreased from 112 to 1.6BU, FVIII activity
increased from 0.26% to 17%, and PTT decreased from 199s to 38s. Three days after
discharge, repeat labs demonstrated Factor VIII activity of 59% and FVIII inhibitor level of
0.00BU. The patient was discharged home on a steroid taper.
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AHA is a rare disease that is challenging to treat. A review of current literature shows
numerous documented cases of successful inhibitor eradication. The large heterogeneity of
reported cases poses significant challenges in the development of a standardized treatment
protocol. Associated preexisting conditions such as malignancy, autoimmune disorders,
pregnancy and previous treatment exposures make conclusions difficult. Another significant
limitation is reporting bias, whereas successfully treated cases are more likely to be
reported. When considering effectiveness of treatment regimens an additional factor to
consider is the spontaneous resolution of inhibitors in approximately 30% of patients.
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Prednisone
10/10 -11/5 80 mg/day
11/6 Begin Taper
Cyclophosphamide
10/12 – 10/21 150 mg
10/22 – 10/27 250 mg
10/28 – 10/31 200 mg
11/1 – 11/2 175 mg
Rituximab
10/17 800 mg
10/24 800 mg
10/31 800 mg
11/7 800 mg
IVIG
10/26 75 g
10/27 75 g
Date
Factor VIII 
activity (norm. 50-
150%)
Factor VIII 
inhibitor (BU)
PTT (norm. 22-36 
seconds)
10/6 0.26 112.00 122
10/11 - 200.00
10/15 0.47 320.00 88
10/16 0.51 288.00 85
10/19 0.53 160.00 87
10/22 0.32 112.00 108
10/23 0.59 - 97
10/25 0.64 40.00 92
10/29 0.47 20.00 117
11/1 0.64 15.00 98
11/5 1.99 6.00 107
11/8 17 1.60 114
11/12 59 0.00 55
12/3 112 0.00 34
Coagulation Studies
INR 1.12
PT (12.1 – 14.5) 21.8
PTT (22 – 36 sec) 199
Mixing Study* Non Corrective
Figure 1. Flowchart in evaluation of acquired hemophilia. AH = acquired hemophilia. LA = lupus
anticoagulant.
Table 3. Initial Coagulation studies on day of hospital admission. *Mixing
study results initially reported as correcting with addition of plasma. Final
result of mixing study were available on day 4 of hospital admission.
Table 1. Treatment regimen
utilized in the eradication of
FVIII Inhibitor. Patient weight
approximately 80 kilograms.
Table 2. Trend of Factor VIII inhibitor activity, Factor VIII
inhibitor levels and PTT. BU = Betstheda units.
Image 1. CT abdomen and pelvis demonstrating the formation of
spontaneous hematoma of the right medial compartment of the thigh
Imaging
